FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2756375477> ?p ?o ?g. }

• W2756375477 endingPage "666" @default.
• W2756375477 startingPage "660" @default.
• W2756375477 abstract "Background and Objectives Recent neurobiological evidences along with clinical observations justify the use of N‐acetylcysteine (NAC) as a medication for craving. The objective of our study was to assess the evidence of efficacy of NAC for craving in substance use disorders in randomized clinical trials (RCTs). Methods Systematic review of the RCTs literature (PROSPERO number 56698) until February, 2017, using MEDLINE, Cochrane Library and clinicaltrials.gov . We included seven RCTs ( n = 245); most with small‐to‐moderate sample sizes. The main outcome was the Hedges’ g for continuous scores in a random‐effects model. Heterogeneity was evaluated with the I 2 and the χ 2 test. Publication bias was evaluated using the Begg's funnel plot and the Egger's test. Meta‐regression was performed using the random‐effects model. Results Comparing NAC versus placebo, NAC was significantly superior for craving symptoms (Hedges’ g = 0.94; 95%CI 0.55–1.33). The funnel plot showed the risk of publication bias was low and between‐study heterogeneity was not significant ( I 2 = 44.4%, p = 0.07 for the χ 2 test). A subgroup analysis performed using meta‐regression showed no particular influence. Discussion and Conclusions NAC was superior to placebo for craving reduction in SUDs. The relatively small number of trials and their heterogeneous methodology were possible limitations; however, these positive thrilling results stimulate further studies for clarifying the potential impact of NAC for craving symptoms in SUDs.Scientific Significance: The safety profile of NAC and favorable tolerability, in addition to being an over‐the‐counter medication, presents with an interesting potential clinical use for craving in SUDs. Scientific Significance The safety profile of NAC and its favorable tolerability, in addition to being anover‐the‐counter medication, presents with an interesting potential clinical use for craving in SUDs. (Am J Addict 2017;26:660–666)" @default.
• W2756375477 created "2017-09-25" @default.
• W2756375477 creator A5041325383 @default.
• W2756375477 creator A5044537051 @default.
• W2756375477 creator A5060330503 @default.
• W2756375477 creator A5066166225 @default.
• W2756375477 creator A5075051012 @default.
• W2756375477 creator A5076331964 @default.
• W2756375477 creator A5078882374 @default.
• W2756375477 date "2017-09-12" @default.
• W2756375477 modified "2023-10-16" @default.
• W2756375477 title "N‐acetylcysteine in the treatment of craving in substance use disorders: Systematic review and meta‐analysis" @default.
• W2756375477 cites W1567339226 @default.
• W2756375477 cites W1889428062 @default.
• W2756375477 cites W1951949051 @default.
• W2756375477 cites W1967292256 @default.
• W2756375477 cites W1969236260 @default.
• W2756375477 cites W1971398808 @default.
• W2756375477 cites W1975799116 @default.
• W2756375477 cites W1992261726 @default.
• W2756375477 cites W1996790468 @default.
• W2756375477 cites W2000825098 @default.
• W2756375477 cites W2018347382 @default.
• W2756375477 cites W2019401805 @default.
• W2756375477 cites W2022274094 @default.
• W2756375477 cites W2028643731 @default.
• W2756375477 cites W2036934626 @default.
• W2756375477 cites W2038083244 @default.
• W2756375477 cites W2056907486 @default.
• W2756375477 cites W2058120764 @default.
• W2756375477 cites W2059140543 @default.
• W2756375477 cites W2069294714 @default.
• W2756375477 cites W2075062326 @default.
• W2756375477 cites W2078377798 @default.
• W2756375477 cites W2088991430 @default.
• W2756375477 cites W2090078976 @default.
• W2756375477 cites W2093041014 @default.
• W2756375477 cites W2102956593 @default.
• W2756375477 cites W2104492171 @default.
• W2756375477 cites W2110075826 @default.
• W2756375477 cites W2119504117 @default.
• W2756375477 cites W2121921751 @default.
• W2756375477 cites W2121945096 @default.
• W2756375477 cites W2124107177 @default.
• W2756375477 cites W2132099678 @default.
• W2756375477 cites W2141541418 @default.
• W2756375477 cites W2318600546 @default.
• W2756375477 cites W3022903699 @default.
• W2756375477 doi "https://doi.org/10.1111/ajad.12620" @default.
• W2756375477 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28898494" @default.
• W2756375477 hasPublicationYear "2017" @default.
• W2756375477 type Work @default.
• W2756375477 sameAs 2756375477 @default.
• W2756375477 citedByCount "56" @default.
• W2756375477 countsByYear W27563754772018 @default.
• W2756375477 countsByYear W27563754772019 @default.
• W2756375477 countsByYear W27563754772020 @default.
• W2756375477 countsByYear W27563754772021 @default.
• W2756375477 countsByYear W27563754772022 @default.
• W2756375477 countsByYear W27563754772023 @default.
• W2756375477 crossrefType "journal-article" @default.
• W2756375477 hasAuthorship W2756375477A5041325383 @default.
• W2756375477 hasAuthorship W2756375477A5044537051 @default.
• W2756375477 hasAuthorship W2756375477A5060330503 @default.
• W2756375477 hasAuthorship W2756375477A5066166225 @default.
• W2756375477 hasAuthorship W2756375477A5075051012 @default.
• W2756375477 hasAuthorship W2756375477A5076331964 @default.
• W2756375477 hasAuthorship W2756375477A5078882374 @default.
• W2756375477 hasBestOaLocation W27563754772 @default.
• W2756375477 hasConcept C118552586 @default.
• W2756375477 hasConcept C126322002 @default.
• W2756375477 hasConcept C142724271 @default.
• W2756375477 hasConcept C168563851 @default.
• W2756375477 hasConcept C17744445 @default.
• W2756375477 hasConcept C187960798 @default.
• W2756375477 hasConcept C197934379 @default.
• W2756375477 hasConcept C199539241 @default.
• W2756375477 hasConcept C204787440 @default.
• W2756375477 hasConcept C27081682 @default.
• W2756375477 hasConcept C2776478404 @default.
• W2756375477 hasConcept C2778375690 @default.
• W2756375477 hasConcept C2779473830 @default.
• W2756375477 hasConcept C2779541405 @default.
• W2756375477 hasConcept C2780439572 @default.
• W2756375477 hasConcept C48856860 @default.
• W2756375477 hasConcept C535046627 @default.
• W2756375477 hasConcept C70410870 @default.
• W2756375477 hasConcept C71924100 @default.
• W2756375477 hasConcept C82605166 @default.
• W2756375477 hasConcept C95190672 @default.
• W2756375477 hasConceptScore W2756375477C118552586 @default.
• W2756375477 hasConceptScore W2756375477C126322002 @default.
• W2756375477 hasConceptScore W2756375477C142724271 @default.
• W2756375477 hasConceptScore W2756375477C168563851 @default.
• W2756375477 hasConceptScore W2756375477C17744445 @default.
• W2756375477 hasConceptScore W2756375477C187960798 @default.
• W2756375477 hasConceptScore W2756375477C197934379 @default.
• W2756375477 hasConceptScore W2756375477C199539241 @default.

• next